Monitoring Parameters (Labs And Vitals) - NAPLEX
- Which laboratory parameter is the primary monitor for digoxin toxicity risk in renal impairment?
- Serum digoxin concentration (plus renal function and potassium). Monitors drug accumulation in renal impairment, with hypokalemia exacerbating toxicity risks.
- Which two labs should be monitored after starting spironolactone for heart failure?
- Serum potassium and serum creatinine. Spironolactone's aldosterone antagonism can cause hyperkalemia and worsen renal function in heart failure patients.
- Which laboratory parameter must be monitored with metformin due to rare but serious toxicity risk?
- Renal function (serum creatinine or eGFR). Assesses kidney function to prevent metformin accumulation and risk of lactic acidosis in impaired clearance.
- Which laboratory parameter is required to monitor for statin-associated hepatotoxicity when indicated?
- ALT (liver transaminases). Elevations in transaminases indicate potential liver injury, prompting evaluation in symptomatic patients or per guidelines.
- Which vital sign should be monitored to detect orthostatic hypotension from alpha-1 blockers?
- Blood pressure (including orthostatic measurements). Alpha-1 blockade causes vasodilation, potentially leading to postural blood pressure drops requiring monitoring.
- Which laboratory test monitors for clozapine-induced agranulocytosis risk?
- Absolute neutrophil count (ANC). Weekly monitoring detects severe neutropenia early, preventing infections from clozapine's agranulocytosis risk.
- Which lab must be monitored with methotrexate therapy to detect myelosuppression?
- CBC (white blood cells, hemoglobin, platelets). Detects reductions in blood cell lines indicating bone marrow suppression, a dose-limiting toxicity of methotrexate.
- Which daily self-monitoring parameter best detects hypoglycemia risk with insulin or sulfonylureas?
- Capillary blood glucose (SMBG). Enables real-time detection of low blood sugar to prevent hypoglycemic episodes in patients on these agents.
- What is the preferred pharmacokinetic exposure target for vancomycin in serious MRSA infections?
- AUC/MIC to (assume MIC ). Optimizes efficacy against MRSA while reducing risks of resistance and toxicity based on pharmacokinetic guidelines.
- Which electrolyte must be monitored closely with ACE inhibitors due to hyperkalemia risk?
- Serum potassium. ACE inhibitors reduce aldosterone, promoting potassium retention and increasing hyperkalemia risk, especially in renal impairment.
- Which aminoglycoside toxicity is most associated with rising serum creatinine during therapy?
- Nephrotoxicity. Rising creatinine indicates renal tubular damage from aminoglycoside accumulation, a common dose-related toxicity.
- Which laboratory parameter is the standard efficacy monitor for diabetes therapy over 3 months?
- Hemoglobin A1c. Provides an average measure of glycemic control over 2-3 months to evaluate long-term diabetes management efficacy.
- What laboratory test is used to monitor warfarin anticoagulation intensity?
- INR. Standardizes prothrombin time to evaluate vitamin K antagonist effects and guide dosing for optimal anticoagulation.
- Which vital sign is the primary monitoring parameter for beta-blocker dose titration?
- Heart rate (and blood pressure). Assesses beta-adrenergic blockade to titrate doses for heart rate reduction and blood pressure control.
- Which laboratory parameter is required to monitor lithium therapy for efficacy and toxicity?
- Serum lithium concentration. Maintains levels within the therapeutic range to ensure mood stabilization while avoiding neurotoxicity.
- Which lab should be monitored with SGLT2 inhibitors to assess renal eligibility and ongoing safety?
- eGFR (renal function). Determines treatment eligibility and monitors for renal adverse effects, as SGLT2 inhibitors affect kidney function.
- Which laboratory parameter is the primary monitor for thyroid hormone replacement dose adjustment?
- TSH (and free in selected situations). TSH levels guide levothyroxine dosing to achieve euthyroid state, with free T4 used in specific clinical scenarios.
- Which lab value should be monitored to assess bleeding risk and marrow suppression with linezolid?
- Platelet count (CBC). Detects thrombocytopenia from myelosuppression, which increases bleeding risk during prolonged therapy.
- Which lab is used to evaluate statin-associated muscle injury when symptoms occur?
- Creatine kinase (CK). Elevated levels confirm muscle damage in symptomatic patients, guiding management of statin-induced myopathy.
- Which two additional labs should be monitored during chronic lithium therapy beyond drug level?
- TSH and serum creatinine (renal function). Lithium can induce hypothyroidism and renal impairment, necessitating periodic screening for these long-term effects.
- Which laboratory parameter is most important to monitor for aminoglycoside nephrotoxicity?
- Serum creatinine (renal function). Reflects glomerular filtration rate changes to detect early nephrotoxic effects from aminoglycoside exposure.
- Which laboratory parameter is the primary safety monitor for unfractionated heparin infusion?
- aPTT (or anti-Xa per institutional protocol). Measures coagulation time to ensure therapeutic anticoagulation and minimize bleeding risk during continuous infusion.
- Which laboratory parameter is used to monitor valproic acid exposure for seizure control?
- Serum valproic acid concentration. Ensures therapeutic levels for anticonvulsant efficacy while minimizing risks of toxicity in epilepsy management.
- Which two parameters are essential to monitor for vancomycin nephrotoxicity and exposure?
- Serum creatinine and vancomycin AUC (or trough per protocol). Tracks renal function for nephrotoxicity detection and drug exposure for efficacy and safety optimization.
- Which laboratory parameter is preferred for monitoring low-molecular-weight heparin when needed?
- Anti-Xa level (LMWH-calibrated). Directly assesses anticoagulant activity for dose adjustment in patients requiring monitoring, such as those with renal impairment or obesity.